Medical Literature Monitoring in Pharmacovigilance

Introduction

Scientific and medical literature has long been recognised as an important source of pharmacovigilance information.

Case reports, observational studies, case series and other publications may contain information relating to suspected adverse reactions that has not been reported through traditional spontaneous reporting channels.

Historically, Marketing Authorisation Holders (MAHs) were responsible for independently screening the scientific literature to identify reportable adverse reactions associated with their products.

This often resulted in substantial duplication of effort because multiple companies reviewed the same journals and publications for similar information.

To improve efficiency and consistency, the European Medicines Agency (EMA) introduced the Medical Literature Monitoring (MLM) programme.

Today, MLM forms an important component of the European pharmacovigilance system and contributes directly to EudraVigilance reporting activities.

Why Literature Monitoring Matters

Not all adverse reactions are reported directly to pharmaceutical companies or health authorities.

Many clinically important observations first appear in:

• Case reports
• Case series
• Observational studies
• Epidemiological research
• Clinical publications

Literature sources may reveal:

• Previously unknown adverse reactions
• Rare adverse reactions
• Changes in frequency
• Emerging risk factors
• Safety concerns in specific populations

Literature monitoring therefore represents an important component of signal detection and benefit–risk monitoring.

Historical Approach to Literature Surveillance

Before the MLM programme, every MAH generally maintained independent literature surveillance activities.

This approach presented several challenges:

• Duplication of effort
• Resource-intensive processes
• Inconsistent case identification
• Variable quality standards
• Repeated review of the same publications

Large journals might be screened by dozens of organisations simultaneously.

Although this approach ensured broad coverage, it was often inefficient.

What is Medical Literature Monitoring?

Medical Literature Monitoring is an EMA-operated programme under which designated literature sources are centrally monitored for selected active substances.

The EMA:

• Reviews designated publications
• Identifies potential adverse reaction reports
• Creates Individual Case Safety Reports
• Submits cases into EudraVigilance

The objective is to improve consistency and reduce duplication across the pharmacovigilance system.

MLM does not replace all literature surveillance activities.

Rather, it centralises specific responsibilities for designated substances and designated literature sources.

Which Products are Covered?

The MLM programme does not apply to every medicinal product.

Coverage is determined by the EMA and focuses on selected active substances.

The EMA publishes information regarding substances included within the programme.

MAHs should understand:

• Whether their products are included
• Which substances are monitored
• Which responsibilities remain with the MAH

Failure to understand programme scope may result in compliance gaps.

How MLM Cases Enter EudraVigilance

When EMA reviewers identify a reportable case within monitored literature:

1. The publication is assessed.
2. Relevant safety information is extracted.
3. An Individual Case Safety Report is created.
4. The report is entered into EudraVigilance.
5. The report becomes available to authorised users.

This process ensures that literature-derived safety information becomes available within the broader European pharmacovigilance ecosystem.

Downloading MLM Cases

Many pharmacovigilance professionals first encounter MLM through EudraVigilance case downloads.

Downloaded MLM cases may support:

• Signal detection
• Aggregate reporting
• Medical review
• Safety surveillance
• Benefit–risk assessment

Organisations should have procedures describing how downloaded MLM cases are managed within their pharmacovigilance systems.

Responsibilities of Marketing Authorisation Holders

One common misconception is that MLM eliminates literature surveillance responsibilities for MAHs.

This is incorrect.

MAHs remain responsible for understanding:

• Programme scope
• Product coverage
• Residual monitoring obligations
• Internal procedures

Responsibilities may include:

• Monitoring literature outside programme coverage
• Reviewing downloaded cases
• Supporting signal detection
• Maintaining documentation
• Ensuring procedural compliance

The precise responsibilities depend upon the products and substances involved.

Literature Cases and Signal Detection

Literature-derived cases can contribute significantly to signal detection activities.

Published case reports may:

• Identify new adverse reactions
• Support existing signals
• Provide mechanistic insights
• Highlight emerging clinical concerns

Consequently, literature information often plays an important role within signal management activities.

For a detailed discussion see:

[[evdas-and-signal-detection]]

Relationship Between MLM and EudraVigilance

MLM and EudraVigilance are closely connected.

A simplified relationship can be described as:

Together these systems support broader pharmacovigilance objectives.

QPPV Oversight

The QPPV is not generally expected to perform literature surveillance activities personally.

However, regulators typically expect the QPPV to understand:

• How literature monitoring is performed
• Which products are covered
• How literature cases are managed
• How signal detection activities utilise literature information
• Whether compliance risks exist

The QPPV should maintain visibility of significant issues affecting literature surveillance processes.

Inspection Perspective

Literature surveillance activities may be reviewed during pharmacovigilance inspections.

Inspectors may assess:

• Literature surveillance procedures
• Programme coverage assessments
• Documentation of responsibilities
• Management of downloaded MLM cases
• Governance arrangements
• Compliance monitoring activities

Inspectors generally expect organisations to demonstrate a clear understanding of their obligations.

Common Inspection Findings

Observed deficiencies may include:

• Unclear programme scope
• Incomplete procedures
• Failure to document responsibilities
• Inadequate oversight
• Failure to manage downloaded literature cases appropriately
• Insufficient governance controls

Many findings arise because organisations incorrectly assume that MLM removes all literature-related obligations.

Practical Considerations

Effective MLM governance commonly includes:

• Defined procedures
• Responsibility matrices
• Coverage assessments
• Periodic review activities
• Training programmes
• Compliance monitoring
• QPPV oversight

These activities help ensure that literature surveillance responsibilities remain appropriately controlled.

Key Takeaways

• Medical literature is an important source of pharmacovigilance information.
• The EMA operates the Medical Literature Monitoring programme for selected substances.
• MLM reduces duplication of effort across the pharmacovigilance system.
• Literature-derived cases are entered into EudraVigilance.
• MAHs continue to retain important literature surveillance responsibilities.
• Literature information contributes to signal detection and benefit–risk monitoring.
• QPPVs are expected to understand how literature monitoring activities are governed.
• Literature surveillance processes may be reviewed during inspections.

Regulatory and GVP Context

MLM activities and the MAH responsibilities that surround them sit within the broader EU legislative and guidance framework:

• GVP Module I — Pharmacovigilance System and Quality System: describes the responsibilities of the QPPV and the need for an accountable PV system.
• GVP Module VI — Collection, Management and Submission of Reports of Suspected Adverse Reactions: addresses sources of information, including scientific literature, and reporting obligations/timelines.
• GVP Module IX — Signal Management: outlines processes for detection, validation, confirmation, assessment and escalation of signals.
• Commission Implementing Regulation (EU) No 520/2012 and related EudraVigilance guidance documents: describe electronic reporting and system functionality.
• EMA Medical Literature Monitoring Guidance: describes the centralised monitoring performed by EMA and the resulting responsibilities for MAHs.

When designing internal processes, MAHs should map their activities to these documents and ensure that literature-derived information is handled in a manner consistent with GVP expectations for collection, processing, reporting and signal management.

Inspection-ready Procedural Checklist for MLM Scope and Case Management

This checklist is intended for MAHs to prepare evidence and demonstrate control over MLM-related obligations during inspections. Items should be present, current, and readily retrievable.

• Governance and System Documentation
• PV System Master File (PSMF) contains:
  • Clear description of MLM responsibilities and interfaces (GVP Module I).
  • List of products/substances included in MLM and MAH responsibilities for each.
• QPPV signed statement of oversight for MLM activities.

• PV Quality Management System references to MLM SOP(s).

• Programme Scope Assessment

• Documented assessment that determines whether the MAH’s product/substance is in the EMA MLM list (dated evidence; include EMA source URL or snapshot).
• Rationale and documented decision for residual monitoring responsibilities (e.g., journals, regions, languages not covered by MLM).

• Coverage map (spreadsheets or database) linking MAH products to EMA MLM substances and literature sources.

• Procedures and SOPs

• Up-to-date SOP(s) covering:
  • Assessment of MLM scope and periodic re-assessment.
  • Export, download, and processing of MLM cases from EudraVigilance.
  • Triage, qualification and case entry into the MAH safety database (if required).
  • Escalation of potential signals to signal management and QPPV.

• Version history, approval signatures, and training records for named staff.

• Operational Evidence of Downloading and Processing

• Logs of EudraVigilance downloads showing frequency (e.g., weekly) and scope filters used.
• Screening logs listing downloaded MLM cases, screening outcome (e.g., reportable / not reportable), reason codes and reviewer initials/dates.
• Case reconciliation records (linking downloaded EV case ID to internal case ID or rationale for no entry).

• QC records demonstrating verification of extracted data and deduplication steps.

• Case Processing and Reporting

• Examples of medical review notes and decision rationales for MLM-derived cases.
• Evidence of expedited reporting decisions and timelines mapped to GVP Module VI requirements and legislation (e.g., serious/unexpected cases flagged and processed).

• Evidence of transmission to EudraVigilance or documentation of why MAH entry was not required (e.g., case already in EV from EMA).

• Signal Management and Escalation

• Logs of potential signals flagged from MLM cases.
• Documentation of triage/validation decisions in accordance with GVP Module IX.
• Records of signal assessments, decisions and actions (e.g., PSUR inclusion, RMP update, further data collection).

• Evidence of escalation to the QPPV and PV governance committees when appropriate.

• Delegation and Agreements

• Contracts/delegation agreements with service providers (e.g., literature vendors, PV databases) that clearly allocate responsibilities for MLM-related activities.

• RACI or responsibility matrix for MLM tasks (who downloads, who screens, who medically reviews, who escalates).

• Training and Competency

• Training records for staff performing MLM downloads, screening, case processing and signal management.

• Evidence of periodic competency checks and SOP refresh training.

• Audit and Quality Oversight

• Recent internal audit or quality review covering MLM processes and corrective actions (if any).

• Metrics and KPIs (e.g., time from download to screening, screening completion rate, number of MLM-derived signals) and management review minutes.

• Retention and Traceability

• Evidence that all MLM processing records are retained according to PV record retention requirements and are retrievable for inspection.
• Audit trails from safety database and document management system showing who changed what and when.

For inspection readiness, have a curated “MLM binder” (electronic or physical) containing the most recent copies of the items above with an index and hyperlinks or page references.

SOP Template — Assessing MLM Programme Scope, Managing Downloaded MLM Cases, Documenting Responsibilities and Escalating Potential Signals

Use this short, inspection-friendly SOP template as a starting point. Expand and adapt to your company-specific PV system, referencing local roles, systems and applicable legislation. Retain version control, authorisation, and training requirements.

Title: SOP — Management of EMA Medical Literature Monitoring (MLM) Cases and Scope Assessment SOP No: [Enter] Effective Date: [Enter] Version: [Enter] Approved by: [Name, Title]

1. Purpose

2. To define the responsibilities and procedures for assessing EMA MLM programme scope for MAH products, downloading and processing MLM cases from EudraVigilance, documenting responsibilities and escalating potential signals in accordance with GVP Module I, GVP Module VI and GVP Module IX, and Commission Implementing Regulation (EU) No 520/2012.

3. Scope

4. Applies to pharmacovigilance personnel, clinical safety staff, medical reviewers, QPPV, and contracted service providers involved in literature surveillance, EudraVigilance downloads, case processing and signal management for MAH products marketed in the EEA.

5. Definitions

6. MLM case: An Individual Case Safety Report (ICSR) created by EMA from monitored literature and submitted into EudraVigilance.
7. Reportable case: A case which meets the definition of a suspected adverse reaction requiring MAH processing or reporting under GVP Module VI and applicable legislation.

8. Screening: Initial triage to determine whether an MLM case requires further action by the MAH.

9. Responsibilities

10. QPPV: Overall oversight and final decision authority for signal escalations (GVP Module I).
11. Head of PV Operations: Operational oversight; ensures downloads are performed and screened per SOP.
12. Designated EV Administrator: Performs scheduled download of MLM cases from EudraVigilance and maintains download logs.
13. Medical Reviewer: Conducts clinical assessment of MLM cases and determines reportability and signal relevance.
14. Signal Management Lead: Receives escalations and coordinates validation/assessment according to GVP Module IX.

15. PV Quality Assurance: Periodic audit and monitoring of adherence to this SOP.

16. Procedure

5.1. Programme Scope Assessment (Initial and Periodic) - Frequency: At SOP baseline and then quarterly or whenever EMA publishes an update to MLM scope. - Steps: 1. Retrieve the current EMA MLM list and guidance (store snapshot in PSMF). Document date and source. 2. Map company products to EMA-listed substances. Record results in an MLM Coverage Matrix (template Appendix A). 3. Identify residual monitoring obligations (journals, languages, regions not covered). 4. Document decisions on whether additional literature monitoring is required and assign responsibilities. 5. Approve coverage assessment by Head of PV Operations and QPPV; file in PSMF.

• References: GVP Module I (PV system), EMA MLM guidance.

5.2. EudraVigilance Download and Initial Processing - Frequency: [default weekly — specify frequency consistent with PV workload and risk profile] - Steps: 1. EV Administrator performs download of MLM cases using standard filters and saves files to a secure, access-controlled location. Record EV export IDs and date/time in the Download Log (Appendix B). 2. Create a Screening Log entry for each MLM case: EV Case ID, substance, MAH product mapping, date downloaded, assigned reviewer. 3. Assign case to a trained screener/medical reviewer within [X working days]. 4. Perform initial deduplication check against company safety database (using exact/patient/medication/event matching) and annotates results in Screening Log. 5. If case is already present in EV from EMA and linked to MAH, document rationale and no duplicate entry required. If MAH has additional information to add, follow company procedures for provision of follow-up to EV (see local SOP for EV submissions).

• References: Commission Implementing Regulation (EU) No 520/2012; GVP Module VI (collection and submission).

5.3. Case Screening and Qualification - Steps: 1. Screeners complete the screening template (Appendix C) capturing: - Reporter type, publication citation, case summary, seriousness criteria, expectedness vs SmPC, plausible causality, concomitant medications, confounding factors. 2. Medical reviewer decides: - Reportable to EudraVigilance by MAH (if not already present and meets reporting criteria). - Non-reportable but relevant for signal detection activities. - No action required. 3. Document decision, sign/date and retain screening template and rationale.

• Timelines: Decisions and entries shall be completed consistent with reporting requirements (see GVP Module VI). Serious/unexpected cases must be identified promptly for potential expedited action.

5.4. Case Entry, Follow-up and Reporting - Steps: 1. For cases requiring MAH entry into internal safety database, complete data entry consistent with company data standards and link to EV Case ID where applicable. 2. For follow-up or additional information requests, attempt to obtain information per company process; log attempts and results. 3. If the MAH determines additional reporting to EV is necessary (e.g., MAH holds primary report), submit as required by internal EV submission SOP. 4. For cases not entered into company database due to duplication, annotate Screening Log and retain supporting rationale.

• References: GVP Module VI; Commission Implementing Regulation (EU) No 520/2012.

5.5. Escalation to Signal Management - Trigger conditions for escalation: - A cluster of MLM cases showing similar events for the same product. - A single serious, unexpected, and medically significant case suggestive of a new safety concern. - Publication of surveillance or epidemiological evidence with potential impact on benefit–risk. - Escalation steps: 1. Medical reviewer documents clinical rationale on the Escalation Form (Appendix D) and notifies the Signal Management Lead and QPPV within [X working days]. 2. Signal Management Lead performs triage/validation per GVP Module IX and documents outcome. 3. If validated, perform signal assessment and propose actions (e.g., further data collection, expedited PSUR input, RMP amendment). 4. Document all decisions, timelines and QPPV sign-off.

• References: GVP Module IX (signal detection, validation and management).

• Documentation and Records

• Retain all screening logs, download logs, screening templates, medical review notes, escalation forms, and related correspondence in the designated PV document management system for the required retention period.

• Ensure audit trail capability on electronic systems.

• Training

• All staff named in this SOP must undergo initial training and periodic refresher training on MLM processes, GVP Module VI and Module IX requirements, and related company SOPs.

• Quality Control and Audit

• Periodic QC checks on a sample of screened MLM cases (e.g., monthly sample) must be performed by PV Quality Assurance.

• Results of QC must be documented and corrective actions taken as needed.

• Appendices

• Appendix A: MLM Coverage Matrix template.
• Appendix B: EudraVigilance Download Log template.
• Appendix C: MLM Case Screening Template.
• Appendix D: Signal Escalation Form.

• Appendix E: RACI matrix for MLM tasks.

• References

• GVP Module I — Pharmacovigilance System and Quality System (EMA).
• GVP Module VI — Collection, Management and Submission of Reports of Suspected Adverse Reactions to Medicinal Products (EMA).
• GVP Module IX — Signal Management (EMA).
• Commission Implementing Regulation (EU) No 520/2012 (EudraVigilance).

• EMA Medical Literature Monitoring Guidance.

• Change History

• [Maintain version control table]

Practical Implementation Notes (Detailed, Operational)

• Download cadence: A weekly automated or manual download is a common operational baseline; increase to daily for high-risk products or following safety concerns or publications.
• Filters and metadata: Save search filters and export parameters used for each download. Keep auditable records of filter settings to show consistent processing.
• Residual monitoring: Maintain a list of journals, languages and regions assessed by the MAH outside the MLM programme. Document frequency and responsible persons for monitoring these sources.
• Deduplication strategy: Use deterministic matching (e.g., EvCaseID, event term, age, country) followed by manual clinical review. Document algorithm settings and manual override rules.
• Case classification taxonomy: Apply a consistent set of reason codes for Screening Log outcomes (e.g., Reportable – MAH entry, Reportable – EV already present, Non-reportable – insufficient information, Not related).
• timeliness tracking: Maintain a KPI dashboard showing time from download to screening completion, from screening to medical review, and from review to escalation/reporting.
• Confidentiality and IPR: Store downloaded literature PDFs in the secure PV document system; ensure copyright compliance and retention justification.
• Vendor oversight: If contracted vendors perform parts of the process (screening, downloads), ensure delegations are explicit, controls exist, and oversight audits are performed.
• Evidence for inspectors: Provide a short navigation sheet demonstrating how to locate the PSMF coverage matrix, the latest EMA MLM scope snapshot, the download log, an example screening template with decision rationale, and an escalation record.

Governance and Roles Discussion

Robust governance clarifies ownership and ensures compliance:

• QPPV accountability: The QPPV must understand and accept responsibility for the adequate performance of MLM-related activities within the MAH’s PV system (GVP Module I). The QPPV should be identifiable on the PSMF and available to inspectors.
• Local operational ownership: Assign named operational owners for downloads, screening and database entry. Use a RACI matrix to prevent ambiguity during inspections.
• Quality assurance integration: QA must include MLM in audit plans, with corrective and preventive action (CAPA) tracking visible to senior management.
• Management review: Regular management reviews should include MLM metrics and any open escalations to demonstrate active governance and resource allocation.

Inspection Relevance — What Inspectors Expect to See

Inspectors will typically require evidence that the MAH:

• Has determined whether (and how) the EMA MLM programme covers their products and has documented this assessment.
• Maintains SOPs describing the operational flow from EV download to screening to reporting and escalation, with clear responsibilities and training records (GVP Module VI and Module I).
• Demonstrates traceability for downloaded MLM cases (download log, screening outcome, medical review and entry or rationale for non-entry).
• Applies GVP Module IX principles when escalating potential signals identified from literature, with documented triage and decision-making.
• Provides evidence of oversight of contracted parties performing MLM work, including delegation agreements and QA checks.
• Retains records and audit trails that show timely actions and decision-making consistent with legal reporting obligations.

Preparing the “MLM binder” described in the checklist will materially reduce inspection friction and demonstrate a controlled system.

References

1. EMA Good Pharmacovigilance Practices (GVP) Module I — Pharmacovigilance System and Quality System.
2. EMA Good Pharmacovigilance Practices (GVP) Module VI — Collection, Management and Submission of Reports of Suspected Adverse Reactions to Medicinal Products.
3. EMA Good Pharmacovigilance Practices (GVP) Module IX — Signal Management.
4. Commission Implementing Regulation (EU) No 520/2012.
5. EMA Medical Literature Monitoring Guidance.
6. EMA EudraVigilance Documentation.
7. ICH E2D Post-Approval Safety Data Management.